文献速递心力衰竭与心肌病

沙库巴曲缬沙坦治疗射血分数降低心衰的成本效果

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
PubMed 文献 · Heart · 2017-12-21

基于多国III期随机对照试验数据,采用决策分析模型从英国、丹麦和哥伦比亚医疗支付方视角评估沙库巴曲缬沙坦对比依那普利治疗HF-REF的终身成本效果。结论认为三国中沙库巴曲缬沙坦相较ACEI可能具有成本效果。

要点

  • 常规支付阈值下具有成本效果的概率三国分别为68%-94%、84%和95%。
  • 结果对死亡率外推、治疗效应持续时间和时间跨度最敏感。

核心结论

  • 在英国、丹麦和哥伦比亚,沙库巴曲缬沙坦对比ACEI治疗HF-REF患者可能具有成本效果。

研究设计与样本

  • 基于多国III期随机对照试验数据开展成本-效用分析,构建决策分析模型外推终身健康相关生活质量、住院率和生存。
  • 从英国、丹麦和哥伦比亚医疗支付方视角评估,主要结局为增量成本效果比(ICER)。

主要发现

  • 确定性敏感性分析显示结果对死亡率外推、治疗效应持续时间和时间跨度最敏感,其他结构变化下大多数场景ICER低于三国支付阈值。
  • 概率敏感性分析显示常规支付阈值下具有成本效果的概率在英国为68%-94%,丹麦84%,哥伦比亚95%。

临床怎么用

  • 在三国医疗体系中,沙库巴曲缬沙坦相较ACEI用于HF-REF患者可能符合成本效果,可支持支付决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic heart failure with reduced ejection fraction (HF-REF) represents a major public health issue and is associated with considerable morbidity and mortality. We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with an ACE inhibitor (ACEI) (enalapril) in the treatment of HF-REF from the perspective of healthcare providers in the UK, Denmark and Colombia. METHODS: A cost-utility analysis was performed based on data from a multinational, Phase III randomised controlled trial. A decision-analytic model was developed based on a series of regression models, which extrapolated health-related quality of life, hospitalisation rates and survival over a lifetime horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER). RESULTS: In the UK, the cost per quality-adjusted life-year (QALY) gained for sacubitril/valsartan (using cardiovascular mortality) was £17 100 (€20 400) versus enalapril. In Denmark, the ICER for sacubitril/valsartan was Kr 174 000 (€22 600). In Colombia, the ICER was COP$39.5 million (€11 200) per QALY gained. Deterministic sensitivity analysis showed that results were most sensitive to the extrapolation of mortality, duration of treatment effect and time horizon, but were robust to other structural changes, with most scenarios associated with ICERs below the willingness-to-pay threshold for all three country settings. Probabilistic sensitivity analysis suggested the probability that sacubitril/valsartan was cost-effective at conventional willingness-to-pay thresholds was 68%-94% in the UK, 84% in Denmark and 95% in Colombia. CONCLUSIONS: Our analysis suggests that, in all three countries, sacubitril/valsartan is likely to be cost-effective compared with an ACEI (the current standard of care) in patients with HF-REF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. McMurray JJV, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2017. PMID: 29269379. doi:10.1136/heartjnl-2016-310661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。